LACTOLOGY FOUNDATION

Pharmacotherapeutic group and indications

Calcium carbonate is a calcium‑containing antacid belonging to ATC class A02AC01. It is used for symptomatic relief of conditions related to gastric acid excess such as heartburn, acid indigestion and dyspepsia, and may also be used as a calcium supplement or phosphate binder depending on product and dose.

In antacid preparations, calcium carbonate acts locally in the gastric lumen by neutralizing hydrochloric acid and increasing gastric pH. At recommended antacid doses in otherwise healthy adults, systemic exposure to calcium is modest.

Pharmacokinetics and passage into breast milk

After oral administration, calcium carbonate is partially dissolved in gastric acid, and a proportion of the released calcium is absorbed from the small intestine. In adults, approximately 15–30% of ingested elemental calcium is absorbed, with wide inter‑individual variability depending on vitamin D status, baseline calcium intake and physiological needs.

Calcium is a normal constituent of human milk, and calcium from medicinal products contributes to the maternal systemic pool. Calcium carbonate and/or absorbed calcium are excreted into breast milk, but at therapeutic antacid doses no clinically relevant increase in milk calcium concentration is expected, and no adverse effects on breastfed infants are anticipated. The calcium content of breast milk displays marked inter‑individual variability (differences of up to about twofold between women have been described) and changes over the course of lactation, particularly during the first 6 weeks postpartum.

Toxicological risk in pregnancy

Calcium carbonate has longstanding clinical use in pregnancy both as an antacid and as a calcium supplement, and controlled data have not shown an increased risk of congenital malformations when used within recommended doses. Historically, calcium carbonate antacids have been classified in pregnancy category A, indicating that adequate and well‑controlled studies have failed to demonstrate a risk to the fetus in the first trimester, with no evidence of risk in later trimesters.

Excessive intake above recommended daily amounts, particularly in combination with vitamin D and other sources of calcium, can lead to maternal hypercalcemia and milk‑alkali syndrome, which in turn may be associated with maternal renal impairment and, in rare cases, neonatal complications such as low birth weight or neonatal seizures.

Toxicological risk during lactation

Toxicological lactation category: I – compatible with breastfeeding; no need to interrupt breastfeeding at therapeutic doses.

Extensive post‑marketing experience and dedicated lactation references consider antacids, including calcium carbonate, as first‑line pharmacologic options for heartburn and dyspepsia in breastfeeding women, when lifestyle and dietary measures are insufficient. At standard antacid doses, maternal use of calcium carbonate is regarded as compatible with breastfeeding, and specific monitoring of the healthy term infant is not required.

Theoretically, a higher calcium content in breast milk might reduce gastrointestinal absorption of non‑heme iron in the breastfed infant, but this effect has not been clearly demonstrated in clinical studies and is not considered a reason to avoid therapeutic antacid use in lactating women. In mothers with normal renal function who respect recommended doses, the risk of clinically significant hypercalcemia or milk‑alkali syndrome is negligible.

Potential risks from overdose or prolonged high‑dose use

Milk‑alkali syndrome is a well‑recognized complication of excessive calcium and absorbable alkali intake, typically associated with high‑dose or chronic use of calcium carbonate supplements and antacids. It is characterized by the triad of hypercalcemia, metabolic alkalosis and varying degrees of renal dysfunction and can lead to nephrocalcinosis or chronic kidney disease if unrecognized.

Case series suggest that daily supplemental calcium intakes exceeding approximately 4 g elemental calcium may predispose to this syndrome, especially in the presence of vitamin D supplementation or renal impairment. During lactation, both mother and infant could theoretically be affected in situations of extreme maternal overuse of calcium‑containing antacids, particularly if the infant is preterm or has underlying renal or metabolic vulnerability, although such cases are rare and preventable by adherence to product labeling.

Clinical recommendations for use during lactation

• Use the lowest effective antacid dose for symptom control and avoid exceeding the maximum daily dose specified in the product information.
• Short‑term, intermittent use for heartburn or dyspepsia in otherwise healthy breastfeeding women is considered safe, and breastfeeding does not need to be interrupted or timed in relation to dosing.
• Caution is advised in women with pre‑existing hypercalcemia, hyperparathyroidism, severe renal impairment or those taking other calcium or vitamin D supplements, due to increased risk of milk‑alkali syndrome.
• In breastfed infants of mothers with very high calcium intake, clinicians should remain alert for nonspecific signs potentially related to hypercalcemia (such as poor feeding, vomiting or lethargy), although the overall risk at recommended maternal doses is extremely low.

Important notice

The toxicological information provided on this site is accurate and up to date at the time of publication. New scientific data and regulatory changes will be reviewed regularly and incorporated into the monograph when relevant.

This lactation‑focused toxicology database is intended for use by healthcare professionals as a specialized reference resource and does not replace individual clinical judgment or patient‑specific risk–benefit assessment.